Dec. 9, 2014, 1:20 PM
- Thinly-traded nano cap Achaogen (AKAO +23.6%) jumps on 6x surge in volume albeit on turnover of only 210K. Micro cap Cempra (CEMP +10.8%) jumps on a 2x surge in volume.
- Both companies are mentioned in a report by SunTrust Robinson Humphrey analysts. They say both firms represent attractive acquisition targets in light of Merck's takeout of Cubist.
- Achaogen is a clinical-stage biopharmaceutical firm developing antibacterials for multi-drug resistant Gram-negative infections. Its lead product is Plazomicin, currently in Phase 3 development.
- Cempra is also a clinical-stage firm developing antibiotics. Its lead product is solithromycin, currently in Phase 3 development for the treatment of bacterial pneumonia.
CEMP vs. ETF Alternatives
Cempra Inc is a clinical-stage pharmaceutical company. It develops antibiotics for acute care & community settings to meet critical medical needs in treatment of bacterial infectious diseases, respiratory tract & chronic staphylococcal infections.
Other News & PR